Rigel Pharmaceuticals | RIGL - Pre Tax Profit


Rigel Pharmaceuticals reported $-1.03M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Anika Therapeutics USD -3.87M 32.43M Mar/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Celldex Therapeutics USD -67.04M 10.44M Sep/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
MacroGenics USD 16.82M 52.97M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Veracyte USD 18.89M 17.64M Sep/2025